European Biotech Acquisition Net Tangible Assets

European Biotech Acquisition (EBAC) currently reports a net tangible assets of $120M as of December 2022. That compares with $-6.7M in the prior-year period — up 1912.7% year over year. Use the charts on this page to explore European Biotech Acquisition's net tangible assets history and peer comparisons.

European Biotech Acquisition's net tangible assets increased from $-6.7M to $120M — a 1912.7% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

European Biotech Acquisition reported $120M in net tangible assets as of December 2022. That compares with $-6.7M in the prior-year period — up 1912.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $120M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for European Biotech Acquisition, and consider following EBAC for alerts when major investors trade the stock.